Ron J Keizer(1), Anthe S Zandvliet(2), Alwin DR Huitema(1)
A simple infrastructure and graphical user interface (GUI) for distributed NONMEM analysis on standard network environments
|
Nabil Semmar, Saik Urien, Bernard Bruguerolle and Nicolas Simon
Independent-model diagnostics for a priori identification and interpretation of outliers from a full pharmacokinetic database: correspondence analysis, Mahalanobis distance and Andrews curves
|
Xu (Steven) Xu and Partha Nandy
Exposure-Response Analysis of Adverse Events in Clinical Trials Using Zero-Inflated Poisson Modeling With NONMEM®.
|
Cian Costello (1), Stefaan Rossenu (2), An Vermeulen (2), Adriaan Cleton (2), Adrian Dunne (1)
A Time Scaling Approach to Develop an In Vitro-In Vivo Correlation (IVIVC) Model Using a Convolution-Based Technique
|
Ricardo Nalda-Molina, Amelia Ramon-Lopez, Belén Valenzuela, Bernardo Miguel-Lillo, Maria Jose Duart, Arturo Soto-Matos
Pharmacokinetic and Pharmacodynamic Model for Drug Induced Transient Transaminitis
|
Ibrahim Ince (1,2), Saskia N. de Wildt (1,6), Dick Tibboel (1), John N. van den Anker (1,4), Daan J. Crommelin (5), Meindert Danhof (2), Catherijne A.J. Knibbe (1,2,3)
Tailor-made drug treatment for children: creation of an infrastructure for data-sharing and population PK-PD modeling
|
Navarro-Fontestad MC1, Fernández-Teruel C2, González-Álvarez I1, Bermejo M1, Casabo VG1.
Estimating the complete AUC and its standard error in sparse sampling designs.
|
Marylore Chenel(1), Karl Brendel(1), Emmanuelle Foos-Gilbert(1), Céline M. Laffont(1) and France Mentré(2)
How to show average bioequivalence of concentrations in a test sample with a reference population pharmacokinetic model?
|
Ekaterina Gibiansky (1), Leonid Gibiansky (2)
Indirect Response Models with Positive Feedback: Equations, Properties, and Possible Applications
|
Martin Boucher
A Bayesian Meta-Analysis of Longitudinal Data in Placebo Controlled Studies with Naproxen
|
Petersson, K., Friberg, L.E., Karlsson, M.O.
Transforming parts of a differential equations system to difference equations as a method for run-time savings in NONMEM VI
|
Emilie Hénin (1), Véronique Trillet-Lenoir (1,2), Brigitte Tranchand (1,3), Michel Tod (1), Pascal Girard (1)
Patient compliance estimated from pharmacokinetic sample: application to Imatinib
|
Andreas V. Groth (1)
Alternative parameterisations of saturable (Emax) models allowing for nesting of non-saturable models
|
Matthew M Hutmacher (1), Roberta Bursi (2), Sunny Chapel (1), Thomas Kerbusch (2)
Implications for animal-human scaling of the parallel elimination profile PK model
|
C. Kloft (1), W. Huisinga (2), H.G. Schaefer (3), P. Noertersheuser (3)
Launch of the Graduate Research Training (GRT) Program 'Pharmacometrics & Computational Disease Modelling' in Germany
|
R.M. Savic (1), P.G. Baverel (1), M.O. Karlsson
A novel bootstrap method for obtaining uncertainty measurement around the nonparametric distribution
|
Paul G Baverel, Radojka M Savic, Mats O Karlsson
Covariate Model Building Method for Nonparametric Estimation Method in NONMEM VI: Application to Simulated Data
|
Angelica L. Quartino (1), Lena E. Friberg (1), Sharon D. Baker (2) and Mats O. Karlsson (1)
Comparison Between using Continuous and Categorical Toxicity Data for Estimation with a Model for Continuous Data
|
Shuying Yang and Misba Beerahee
Clinical Trial Simulation to Estimate the Sample Size for Investigation of the Impact of a Drug A on the Pharmacokinetics of Methotrexate, a common co-medication used in Rheumatoid Arthritis (RA)
|
